Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT226 in advanced solid tumors and breast cancer
NCT00600275Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of BGT226 in solid tumor, breast cancer, Cowden syndrome (CS), sponsored by Novartis. Started Dec 2007; status: completed.
02
Drugs
BGT226
03
Conditions
solid tumorbreast cancerCowden syndrome (CS)
Beyond the preview
Go deeper on NCT00600275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600275.